Reported decisions by AstraZeneca PLC and Novavax, Inc. to alter development and launch strategies for their coronavirus vaccines may not necessarily affect the US campaign against the virus, but could upset global efforts, as well as the US place in them.
With US vaccine supply now outpacing demand, the immediate domestic need for another product is waning. But the impact of...







